---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-24-000001"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:06:58.620370+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Aurinia preliminary Q4 net product revenue $42M (+49% YoY); FY23 $159M; guides FY24 $200-220M

## Summary
- Preliminary net product revenue Q4 2023: ~$42M, up 49% YoY from $28.3M; full-year ~$159M, up 53% from $103.5M.
- Total revenue Q4: ~$45M (+59% YoY); full-year ~$176M (+31% YoY); cash & investments ~$351M at year-end.
- Guides 2024 net product revenue $200-220M; targets cash flow positive in H2 2024.
- Patients on LUPKYNIS therapy: ~2,066 at Dec 31, 2023, up from 1,525 a year earlier; 438 PSFs added in Q4.
- Strategic review process ongoing; no further updates on potential sale or merger at this time.

## SEC filing metadata
- accession: 0001600620-24-000001
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/0001600620-24-000001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/auph-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-24-000001
- JSON: https://secwatch.observer/filing/0001600620-24-000001.json
- Plain text: https://secwatch.observer/filing/0001600620-24-000001.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2023 results: revenue approximately $45 million and $176 million. Guidance initiated.
  - Period: fourth quarter and full-year 2023
  - Revenue: approximately $45 million and $176 million
  - Guidance: initiated
  - Result: preliminary results
  source text: AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2023 NET REVENUE RESULTS Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/0001600620-24-000001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.